Press Release
« Back
Manhattan Pharmaceuticals' Alan G. Harris, MD To Chair Drug Development for Obesity Conference
Feb 12, 2007
NEW YORK, NY FEB 12, 2007 - Manhattan Pharmaceuticals, Inc. (AMEX: MHA) today announced that Alan G. Harris, MD, PhD, the company's Chief Medical Officer, will co-chair the upcoming two-day conference on Drug Development for Obesity: Key Strategies for Effective Drug Discovery. The event will be held February 12-13 at the Kensington Marriott Hotel in London, UK. In addition to his leadership responsibilities at the conference, Dr. Harris will also give a presentation titled: "Obesity: An Underlying Cause of the Metabolic Syndrome" which will be held Tuesday, February 13 at 9:50am GMT. Keynote speakers to be featured at the conference include Prof Jon Arch, University of Buckingham and Prof Steve Bloom, Imperial College London. Other expert speakers include Dr Joannes Linders, Johnson & Johnson; Dr Antonio Tataranni, sanofi-aventis; Dr. Rafaella Balena, Hoffman La-Roche; and many other industry experts from companies involved in leading obesity research. To learn more about the conference, or to request a brochure, please go to http://www.marcusevans.com/events/CFEventinfo.asp?EventID=11707 or visit the Manhattan Pharmaceuticals, Inc. website at http://www.manhattanpharma.com.
About Manhattan Pharmaceuticals, Inc.
Manhattan Pharmaceuticals, Inc., a development-stage pharmaceutical company, acquires and develops proprietary prescription drugs for large, underserved patient populations. In view of the worldwide obesity epidemic, the company is developing OE, an orally administered novel therapeutic for the treatment of both common obesity and morbid obesity. To meet the needs of other major, underserved medical markets Manhattan Pharmaceuticals is also developing PTH (1-34), a peptide believed to be a regulator of epidermal cell growth, for the treatment of psoriasis, and Propofol Lingual Spray, a convenient, proprietary lingual spray formulation of propofol, the world's best-selling general anesthetic, as a sedative-hypnotic for use during diagnostic and therapeutic procedures. (http://www.manhattanpharma.com)
